EuroBiotech: More Articles of Note

A pile of newspapers

> 4D Pharma (LON:DDDD) began a Phase I trial of its Crohn’s disease candidate. The study marks the start of the process of finding out whether 4D’s idea of treating the digestive tract condition with live bacteria works in humans. 4D, which has dosed the first patient, has built two stages in the study. The first is a 7-day, 10-person, single-dose trial. If that goes well, 4D will advance into a multi-dose study. Release

> Jim Mellon’s oncology investment vehicle SalvaRx (LON:SALV) confirmed one of its portfolio firms is due to enter the clinic. The company, iOx Therapeutics, is a University of Oxford spin-out with a lead candidate it sees as complementary to PD-1 inhibitors. SalvaRx CEO Ian Walters was involved in the development of anti-PD-1 monoclonal antibody Opdivo during his time at Bristol-Myers Squibb ($BMY). Release

> Hansa Medical (STO:HMED) reported topline data from an ongoing Phase II trial of its kidney transplant drug IdeS. None of the 10 patients who received a single dose of IdeS before their transplant surgery has experienced delayed graft function or poor creatine levels. Hansa will follow the patients for 6 months. The study is expected to be finalized before the end of the year. Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> The financial aftershocks of Pfizer’s ($PFE) $14 billion takeover of Medivation ($MDVN) spread all the way to Israel. There, Clal Biotech (TLV:CBI) saw its stock price rise 8% on the back of the news. The uptick occurred because Clal owns 53% of CureTech, a biotech that has an agreement with Medivation for cancer drug pidilizumab. Pfizer highlighted its interest in using pidilizumab in immuno-oncology combinations in its release to unveil the Medivation deal. Globes

> Jan Nilsson left NeuroVive Pharmaceutical (STO:NVP). Nilsson served as chief operating office of the Swedish mitochondrial medicine company, even stepping up to interim CEO at one point. But with Erik Kinnman now occupying the CEO chair, a reorganization has resulted in the firm deciding it no longer needs a COO, according to NeuroVive. Release

> Ablynx (EBR:ABLX) confirmed it is hedging its bets as it heads toward the day AbbVie ($ABBV) will decide whether to pick up its rheumatoid arthritis drug. “Ablynx is currently preparing the complete data package for AbbVie but understandably, in our view, in parallel is preparing Phase III plans and exploring new partnership scenarios in case the option is declined,” Jefferies Analyst Peter Welford wrote in a note. Release

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.